JSC Grindeks subsidiary in Lithuania, Ltd Grindeks Kalceks, has received the European Business Masters 2026 A+ certificate from business data and analytics company Okredo. The evaluation recognizes the company as an A+ class business leader in the Baltic region within its size and industry category.
The A+ rating reflects the company’s:
- Financial strength and creditworthiness
- Ability to maintain sustainable business development while adapting to changing market conditions
- Responsible business practices
- Commitment to managing environmental impact in line with broader market trends
Leadership Perspective: Commitment to Sustainable Growth
“This recognition is another confirmation of the consistent work of our team and the principles that guide our business – reliability, responsible growth and long-term cooperation with our partners. Operating in a highly regulated and competitive pharmaceutical environment requires both financial discipline and the ability to adapt to changing market conditions. We are pleased that these efforts have once again been recognised externally.”
– Aurimas Motiejūnas, Director of Ltd Grindeks Kalceks
The European Business Masters 2026 certification follows other recent recognition received by the company in Lithuania:
- Strongest in Lithuania (2026)
- Reliable Employer recognition (2025)
About JSC Grindeks
JSC Grindeks is the parent company of the international pharmaceutical group Grindeks. The Group is engaged in the research, development, manufacturing, and commercialization of original medicines, generic medicines, and active pharmaceutical ingredients.
- Structure & Reach: The Grindeks Group comprises JSC Grindeks and 37 subsidiaries—including JSC Kalceks (Latvia), JSC Tallinna Farmaatsiatehas (Estonia), and HBM Pharma s.r.o. (Slovakia)—as well as 11 representative offices.
- Specialization: Focuses on therapeutic areas including cardiovascular diseases, central nervous system disorders, oncology, dermatology, and diabetes. JSC Kalceks focuses on medicines for the hospital segment, while JSC Tallinna Farmaatsiatehas specializes in ointments.
- Global Footprint: Products are exported to more than 100 countries worldwide, with primary markets across the European Union, Australia, the United Arab Emirates, Israel, and CIS countries.
